Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

IMUXIMMUNIC, INC.

Nasdaq · CIK 0001280776
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts314

Identity from submissions API

NameIMMUNIC, INC.
CIK0001280776
TickersIMUX
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN562358443
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(332) 255-9818
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • VITAL THERAPIES INC (2004-02-18T05:00:00.000Z → 2019-04-10T04:00:00.000Z)
Business address
1200 AVENUE OF THE AMERICAS
SUITE 200
NEW YORK
X1
10036
United States
Mailing address
1200 AVENUE OF THE AMERICAS
SUITE 200
NEW YORK
X1
10036
United States

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

837 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000947871-26-001032 005-88651 261563240 34 18044
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-128375 005-88651 261561511 34 20037
2026-11-13 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000895421-26-000348 005-88651 261554117 34 8002
2026-11-13 8-K 8-K 2.02,9.01 0001493152-26-051543 001-36201 261549058 34 306180 1 1
2026-11-13 10-Q 10-Q 0001280776-26-000021 001-36201 261548983 34 14097913 1 1
2026-11-05 8-K e665870_8k-immunic.htm 7.01,9.01 0001193805-26-001432 001-36201 261525098 34 10629141 1 1
2026-11-02 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001716774-26-000028 005-88651 261510050 34 9018
2026-10-01 S-8 e665795_s8-immunic.htm 0001193805-26-001316 333-299232 261431352 33 418301 1 1
2026-09-18 4 xslF345X06/e665786_4-thorvald.xml 0001193805-26-001256 6077
2026-09-18 4 OWNERSHIP DOCUMENT 0000921895-26-002590 28874
2026-09-11 8-K e665777_8k-immunic.htm 5.02,9.01 0001193805-26-001219 001-36201 261375264 34 187131 1 1
2026-09-09 8-K e665768_8k-immunic.htm 7.01,9.01 0001193805-26-001196 001-36201 261366882 34 11499399 1 1
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000947871-26-000800 005-88651 261283939 34 19166
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-097293 005-88651 261283062 34 11169
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001831942-26-000038 005-88651 261282046 34 15850
2026-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001213900-26-088748 005-88651 261270261 34 21539
2026-08-12 S-8 e665620_s8-immunic.htm 0001193805-26-001078 333-298264 261267437 33 229782 1 1
2026-08-11 8-K e665684_8k-immunic.htm 2.02,5.02,7.01,9.01 0001193805-26-001071 001-36201 261260588 34 381263 1 1
2026-08-11 10-Q 10-Q 0001280776-26-000018 001-36201 261260551 34 13743237 1 1
2026-08-10 4 xslF345X06/e665686_4-ridloff.xml 0001193805-26-001069 5553
2026-08-10 3 xslF345X06/e665685_3-ridloff.xml 0001193805-26-001068 3256
2026-08-06 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-092235 005-88651 261251027 34 19834
2026-08-04 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001390202-26-000013 005-88651 261240485 34 12392
2026-07-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001716774-26-000017 005-88651 261178636 34 9111
2026-07-14 8-K e665650_8k-immunic.htm 7.01,9.01 0001193805-26-000966 001-36201 261172563 34 7555611 1 1
2026-07-07 4 xslF345X06/e665635_4-skerjanec.xml 0001193805-26-000932 5565
2026-07-07 4 xslF345X06/e665634_4-rudick.xml 0001193805-26-000931 5526
2026-07-07 4 xslF345X06/e665633_4-phillips.xml 0001193805-26-000930 5540
2026-07-07 4 xslF345X06/e665632_4-jorg.xml 0001193805-26-000929 5518
2026-07-07 4 xslF345X06/e665631_4-congleton.xml 0001193805-26-000928 5522
2026-07-06 8-K e665619_8k-immunic.htm 5.02 0001193805-26-000916 001-36201 261156204 34 187167 1 1
2026-06-29 4 xslF345X06/e665612_4-congleton.xml 0001193805-26-000892 5992
2026-06-29 4 xslF345X06/e665611_4-skerjanec.xml 0001193805-26-000891 5965
2026-06-29 4 xslF345X06/e665610_4-rudick.xml 0001193805-26-000890 5926
2026-06-29 4 xslF345X06/e665609_4-howson.xml 0001193805-26-000889 5794
2026-06-29 4 xslF345X06/e665608_4-jorg.xml 0001193805-26-000888 5918
2026-06-29 4 xslF345X06/e665607_4-phillips.xml 0001193805-26-000887 5940
2026-06-29 4 xslF345X06/e665606_4-jason.xml 0001193805-26-000886 6022
2026-06-29 4 FORM 4 0001193805-26-000885 6120
2026-06-29 4 xslF345X06/e665604_4-vitt.xml 0001193805-26-000884 6033
2026-06-29 4 xslF345X06/e665603_4-bonney.xml 0001193805-26-000883 6008
2026-06-29 8-K e665616_8k-immunic.htm 5.02,5.07,9.01 0001193805-26-000882 001-36201 261135731 34 441906 1 1
2026-06-01 4 xslF345X06/e665512_4-lundgren.xml 0001193805-26-000731 5975
2026-06-01 3 xslF345X06/e665511_3-lundgren.xml 0001193805-26-000730 637413
2026-05-29 DEF 14A e665517_def14a-immunic.htm 0001193805-26-000719 001-36201 261045235 34 1072825
2026-05-28 8-K e665514_8k-immunic.htm 7.01,9.01 0001193805-26-000703 001-36201 261028530 34 3056612 1 1
2026-05-27 8-K e665513_8k-immunic.htm 5.02,7.01,9.01 0001193805-26-000696 001-36201 261022135 34 372785 1 1
2026-05-19 3 xslF345X06/e665491_3-bonney.xml 0001193805-26-000660 17836
2026-05-19 8-K e665479_8k-immunic.htm 5.02,7.01,9.01 0001193805-26-000645 001-36201 26995847 34 223165 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-002364 005-88651 26988712 34 11298
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-001364 005-88651 26983860 34 11786
2026-05-13 8-K e665461_8k-immunic.htm 2.02,9.01 0001193805-26-000593 001-36201 26970873 34 263013 1 1
2026-05-13 10-Q 10-Q 0001280776-26-000010 001-36201 26970823 34 12845148 1 1
2026-05-06 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-056411 005-88651 26950045 34 18676
2026-05-04 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001473 333-294855 26940133 33 1847
2026-05-01 CORRESP filename1.htm 0001193805-26-000555 11584
2026-04-30 S-3/A e665413_s3a-immunic.htm 0001193805-26-000550 333-294855 26927214 33 323992
2026-04-29 4 xslF345X06/e665406_4-panzara.xml 0001193805-26-000529 5861
2026-04-29 3 xslF345X06/e665405_3-panzara.xml 0001193805-26-000527 23626
2026-04-28 8-K e665394_8k-immunic.htm 5.02,7.01,9.01 0001193805-26-000516 001-36201 26903070 34 440603 1 1
2026-04-23 8-K e665386_8k-immunic.htm 3.03,5.03,8.01,9.01 0001193805-26-000495 001-36201 26885710 34 223531 1 1
2026-04-22 10-K/A e665391_10ka-immunic.htm 0001193805-26-000493 001-36201 26884513 34 752822 1 1
2026-04-17 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-002262 005-88651 26869953 34 27161
2026-04-14 8-K e665361_8k-immunic.htm 5.07,8.01 0001193805-26-000461 001-36201 26860867 34 188097 1 1
2026-04-10 8-K e665332_8k-immunic.htm 5.02,9.01 0001193805-26-000437 001-36201 26854846 34 220314 1 1
2026-04-09 S-8 e665230_s8-immunic.htm 0001193805-26-000426 333-294952 26852019 33 438674 1 1
2026-04-06 UPLOAD filename1.pdf 0000000000-26-003455 333-294855 40136
2026-04-02 S-3 e665266_s3-immunic.htm 0001193805-26-000400 333-294855 26834283 33 619268 1 1
2026-04-01 8-K e665306_8k-immunic.htm 8.01,9.01 0001193805-26-000382 001-36201 26824649 34 205716 1 1
2026-03-31 3 xslF345X06/e665297_3-congleton.xml 0001193805-26-000381 3227
2026-03-31 8-K e665296_8k-immunic.htm 5.02,7.01,9.01 0001193805-26-000370 001-36201 26816818 34 217614 1 1
2026-03-04 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-26-001332 005-88651 26721442 34 14223
2026-03-04 D xslFormDX01/primary_doc.xml 06b 0001193805-26-000217 021-575474 26721252 33 28713
2026-03-02 DEF 14A e665189_def14a-immunic.htm 0001193805-26-000201 001-36201 26708199 34 233202
2026-02-27 3 OWNERSHIP DOCUMENT 0000921895-26-000568 40961
2026-02-27 3 OWNERSHIP DOCUMENT 0000921895-26-000567 3079
2026-02-26 10-K 10-K 0001280776-26-000005 001-36201 26681695 34 25477687 1 1
2026-02-26 8-K e665186_8k-immunic.htm 2.02,9.01 0001193805-26-000181 001-36201 26681631 34 263524 1 1
2026-02-24 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001831942-26-000012 005-88651 26672349 34 15913
2026-02-24 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001493152-26-007882 005-88651 26671764 34 24497
2026-02-20 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0000921895-26-000531 005-88651 26661737 34 65361
2026-02-20 PRE 14A e665172_pre14a-immunic.htm 0001193805-26-000167 001-36201 26661031 34 227241
2026-02-20 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-26-018848 005-88651 26660812 34 22776
2026-02-19 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-26-018443 005-88651 26654902 34 47280
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-26-001176 005-88651 26642661 34 10826
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-26-000467 005-88651 26641671 34 10760
2026-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-015336 005-88651 26634383 34 11095
2026-02-13 8-K e665154_8k-immunic.htm 1.01,3.02,5.02,8.01,9.01 0001193805-26-000129 001-36201 26628842 34 1344545 1 1
2026-02-02 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001716774-26-000009 005-88651 26586231 34 8922
2026-01-06 8-K e665076_8k-immunic.htm 3.01 0001193805-26-000011 001-36201 26511439 34 188527 1 1
2026-01-05 8-K e665087_8k-immunic.htm 5.02,9.01 0001193805-26-000007 001-36201 26507478 34 425227 1 1
2025-12-08 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-25-000336 005-88651 251555161 34 10004
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-005186 005-88651 251489015 34 10837
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-006917 005-88651 251484112 34 24107
2025-11-13 8-K e664954_8k-immunic.htm 2.02,9.01 0001193805-25-001570 001-36201 251475403 34 280201 1 1
2025-11-13 10-Q 10-Q 0001280776-25-000017 001-36201 251475388 34 13231499 1 1
2025-11-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-25-107607 005-88651 251462437 34 29047
2025-09-25 8-K e664856_8k-immunic.htm 8.01,9.01 0001193805-25-001357 001-36201 251340217 34 3619221 1 1
2025-08-27 S-8 e664796_s8-immunic.htm 0001193805-25-001239 333-289884 251265245 33 229139 1 1
2025-08-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-003550 005-88651 251221345 34 11148
2025-08-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-078722 005-88651 251220338 34 11356
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-002282 005-88651 251218549 34 29938
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-004879 005-88651 251217624 34 27614
2025-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003508 005-88651 251204579 34 13123
2025-08-08 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-002136 005-88651 251198364 34 15993
2025-08-07 10-Q 10-Q 0001280776-25-000012 001-36201 251191474 34 12593794 1 1
2025-08-07 8-K e664768_8k-immunic.htm 2.02,8.01,9.01 0001193805-25-001164 001-36201 251191442 34 16121688 1 1
2025-07-31 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001085146-25-004384 005-88651 251171436 34 8782
2025-07-18 4 FORM 4 0001193805-25-001069 15616
2025-07-18 4 xslF345X05/e664708_4-duane.xml 0001193805-25-001068 15574
2025-07-18 4 xslF345X05/e664707_4-vitt.xml 0001193805-25-001067 15551
2025-07-18 4 xslF345X05/e664706_4-muehler.xml 0001193805-25-001066 15578
2025-07-18 4 xslF345X05/e664705_4-jason.xml 0001193805-25-001065 15518
2025-07-11 8-K e664690_8k-immunic.htm 5.02 0001193805-25-001008 001-36201 251119550 34 188193 1 1
2025-06-27 8-K e664657_8k-immunic.htm 3.01 0001193805-25-000943 001-36201 251087854 34 188606 1 1
2025-06-20 4/A xslF345X05/e664640_4a-jason.xml 0001193805-25-000925 7322
2025-06-20 4/A FORM 4 0001193805-25-000924 5889
2025-06-20 4/A xslF345X05/e664638_4a-vitt.xml 0001193805-25-000923 8570
2025-06-20 4/A xslF345X05/e664637_4a-duane.xml 0001193805-25-000922 5721
2025-06-20 4/A xslF345X05/e664636_4a-muehler.xml 0001193805-25-000921 5851
2025-06-16 4 xslF345X05/e664632_4-duane.xml 0001193805-25-000885 5096
2025-06-09 4 xslF345X05/e664612_4-howson.xml 0001193805-25-000843 5261
2025-06-09 4 xslF345X05/e664611_4-skerjanec.xml 0001193805-25-000842 5432
2025-06-09 4 xslF345X05/e664610_4-rudick.xml 0001193805-25-000841 5393
2025-06-09 4 xslF345X05/e664609_4-toernsen.xml 0001193805-25-000840 5432
2025-06-09 4 xslF345X05/e664608_4-jason.xml 0001193805-25-000839 7022
2025-06-09 4 xslF345X05/e664607_4-jorg.xml 0001193805-25-000838 5385
2025-06-09 4 FORM 4 0001193805-25-000837 5589
2025-06-09 4 xslF345X05/e664604_4-duane.xml 0001193805-25-000836 5421
2025-06-09 4 xslF345X05/e664603_4-phillips.xml 0001193805-25-000835 5407
2025-06-09 4 xslF345X05/e664602_4-muehler.xml 0001193805-25-000834 5551
2025-06-06 4 xslF345X05/e664605_4-vitt.xml 0001193805-25-000821 8270
2025-06-05 4 xslF345X05/e664594_4-jorg.xml 0001193805-25-000800 7057
2025-06-04 4 FORM 4 0001193805-25-000788 7153
2025-06-04 8-K e664589_8k-immunic.htm 5.02,5.07,9.01 0001193805-25-000787 001-36201 251023183 34 470309 1 1
2025-06-04 4 xslF345X05/e664585_4-rudick.xml 0001193805-25-000786 5071
2025-05-30 8-K FORM 8-K 1.01,7.01,9.01 0001193805-25-000757 001-36201 251011726 34 973858 1 1
2025-05-30 424B5 e664565_424b5-immunic.htm 0001193805-25-000756 333-275717 251011711 33 741959
2025-05-28 424B5 e664548_424b5-immunic.htm 0001193805-25-000731 333-275717 25996155 33 737043
2025-05-28 8-K e664552_8k-immuniclaunch.htm 8.01,9.01 0001193805-25-000730 001-36201 25995556 34 4709888 1 1
2025-05-15 10-Q 10-Q 0001280776-25-000008 001-36201 25952907 34 11909801 1 1
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-003220 005-88651 25951325 34 25506
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-072015 005-88651 25948802 34 10568
2025-04-30 8-K e664445_8k-immunic.htm 8.01,9.01 0001193805-25-000582 001-36201 25891014 34 9406213 1 1
2025-04-22 DEFA14A e664424_defa14a-immunic.htm 0001193805-25-000542 001-36201 25858564 34 281060
2025-04-22 DEF 14A e664292_def14a-immunic.htm 0001193805-25-000541 001-36201 25858555 34 960441
2025-04-09 424B5 e664312_424b5-immunic.htm 0001193805-25-000455 333-275717 25826005 33 594670
2025-04-09 8-K e664373_8k-immunic.htm 1.01,3.02,7.01,9.01 0001193805-25-000454 001-36201 25825989 34 665830 1 1
2025-03-31 10-K 10-K 0001280776-25-000005 001-36201 25789201 34 21891989 1 1
2025-02-20 8-K e664213_8k-immunic.htm 8.01,9.01 0001193805-25-000212 001-36201 25643282 34 3655406 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-25-000049 005-88651 25625180 34 9646
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-001377 005-88651 25624428 34 26524
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-000878 005-88651 25612697 34 12571
2025-01-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000155 005-88651 25575633 34 6344
2025-01-13 8-K e664134_8k-immunic.htm 8.01,9.01 0001193805-25-000038 001-36201 25524976 34 17001358 1 1
2024-12-18 8-K e664091_8k-immunic.htm 5.02,9.01 0001193805-24-001496 001-36201 241559784 34 1079687 1 1
2024-12-09 4/A xslF345X05/e664066_4a-duane.xml 0001193805-24-001448 5748
2024-12-06 4 xslF345X05/e664062_4-duane.xml 0001193805-24-001444 5552
2024-12-06 4 xslF345X05/e664061_4-muehler.xml 0001193805-24-001443 5556
2024-12-06 4 xslF345X05/e664060_4-jason.xml 0001193805-24-001442 5521
2024-12-06 4 xslF345X05/e664059_4-vitt.xml 0001193805-24-001441 5523
2024-12-06 4 FORM 4 0001193805-24-001440 5594
2024-11-14 SC 13G/A d11530437_13g-a.htm 0000919574-24-006770 005-88651 241464611 34 165851
2024-11-14 SC 13G/A JANUS AMENDMENT 0001274173-24-000115 005-88651 241459419 34 13138
2024-11-14 SC 13G/A p24-3275sc13ga.htm 0000902664-24-006505 005-88651 241457043 34 63641
2024-11-13 4 xslF345X05/e664024_4-rudick.xml 0001193805-24-001335 4610
2024-11-12 SC 13G/A UnitedStates_13G__ImmunicInc.txt 0000932471-24-001034 005-88651 241447584 34 6637
2024-11-12 SC 13G IMMUNIC, INC. 0000902664-24-006400 005-88651 241444197 34 80737
2024-11-07 10-Q 10-Q 0001280776-24-000018 001-36201 241433086 34 11532008 1 1
2024-11-07 8-K e663991_8k-immunic.htm 2.02,8.01,9.01 0001193805-24-001316 001-36201 241433035 34 4254814 1 1
2024-11-04 SC 13G/A UnitedStates_13G__ImmunicInc.txt 0000932471-24-000433 005-88651 241421705 34 5717
2024-10-22 8-K e663960_8k-immunic.htm 8.01,9.01 0001193805-24-001257 001-36201 241384641 34 3604256 1 1
2024-09-10 8-K e663880_8k-immunic.htm 8.01,9.01 0001193805-24-001102 001-36201 241290124 34 18099914 1 1
2024-09-03 8-K e663859_8k-immunic.htm 1.01,9.01 0001193805-24-001079 001-36201 241272120 34 202243 1 1
2024-08-08 10-Q 10-Q 0001280776-24-000014 001-36201 241186034 34 11453023 1 1
2024-08-08 8-K e663826_8k-immunic.htm 2.02,8.01,9.01 0001193805-24-001007 001-36201 241185909 34 3811950 1 1
2024-07-24 4 xslF345X05/e663799_4-skerjanec.xml 0001193805-24-000961 8021
2024-07-24 3 xslF345X02/e663798_3-skerjanec.xml 0001193805-24-000960 3166
2024-07-24 8-K e663800_8k-immunic.htm 5.02,9.01 0001193805-24-000957 001-36201 241136058 34 231722 1 1
2024-07-12 4 xslF345X05/e663770_4-jason.xml 0001193805-24-000914 5661
2024-07-12 3 xslF345X02/e663769_3-jason.xml 0001193805-24-000913 3099
2024-07-09 8-K e663765_8k-immunic.htm 5.02,9.01 0001193805-24-000893 001-36201 241106299 34 236805 1 1
2024-07-02 S-8 e663743_s8-immunic.htm 0001193805-24-000874 333-280661 241095247 33 463765
2024-06-13 8-K e663709_8k-immunic.htm 5.07 0001193805-24-000791 001-36201 241039660 34 199653 1 1
2024-06-12 4 xslF345X05/e663707_4-jorg.xml 0001193805-24-000788 5390
2024-06-12 4 xslF345X05/e663706_4-phillips.xml 0001193805-24-000787 5412
2024-06-12 4 xslF345X05/e663705_4-rudick.xml 0001193805-24-000786 5398
2024-06-12 4 xslF345X05/e663704_4-toernsen.xml 0001193805-24-000785 5437
2024-06-12 4 xslF345X05/e663703_4-howson.xml 0001193805-24-000784 5266
2024-06-10 424B5 e663697_424b5-immunic.htm 0001193805-24-000772 333-275717 241032682 33 425613
2024-05-31 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-05-31 17:00:00 9999999995-24-001689 333-275717 241011839 33 1855
2024-05-29 CORRESP filename1.htm 0001193805-24-000720 5258
2024-05-24 S-3/A PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 0001193805-24-000704 333-275717 24984297 33 376745
2024-05-08 10-Q 10-Q 0001280776-24-000009 001-36201 24924240 34 5434038 1 1
2024-05-08 8-K e663589_8k-immunic.htm 2.02,8.01,9.01 0001193805-24-000605 001-36201 24924147 34 3907119 1 1
2024-04-30 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-04-30 17:00:00 9999999995-24-001212 333-277040 24899793 33 1854
2024-04-30 424B3 e663565_424b3-immunic.htm 0001193805-24-000582 333-277040 24898567 33 220843
2024-04-26 CORRESP filename1.htm 0001193805-24-000570 5432
2024-04-23 DEF 14A e663535_def14a-immunic.htm 0001193805-24-000551 001-36201 24865460 34 541374
2024-03-08 8-K e619340_8k-immunic.htm 5.03,5.07,9.01 0001193805-24-000341 001-36201 24734304 34 215750 1 1
2024-03-06 4 xslF345X05/e619339_4-howson.xml 0001193805-24-000325 16600
2024-03-06 4 xslF345X05/e619338_4-duane.xml 0001193805-24-000324 25219
2024-03-06 4 xslF345X05/e619337_4-phillips.xml 0001193805-24-000323 16734
2024-03-06 4 xslF345X05/e619336_4-vitt.xml 0001193805-24-000322 16743
2024-03-06 4 xslF345X05/e619335_4-muehler.xml 0001193805-24-000321 19140
2024-03-06 4 FORM 4 0001193805-24-000320 21323
2024-03-06 4 xslF345X05/e619333_4-joerg.xml 0001193805-24-000319 14797
2024-03-06 4 xslF345X05/e619332_4-toernsen.xml 0001193805-24-000318 8401
2024-03-01 S-3/A e619307_s3a-immunic.htm 0001193805-24-000288 333-277040 24709737 33 270411
2024-02-28 4 xslF345X05/e619306_4-vitt.xml 0001193805-24-000282 5257
2024-02-22 10-K 10-K 0001280776-24-000004 001-36201 24662213 34 15621333 1 1
2024-02-22 8-K e619294_8k-immunic.htm 2.02,8.01,9.01 0001193805-24-000257 001-36201 24662211 34 4273753 1 1
2024-02-21 UPLOAD filename1.pdf 0000000000-24-001995 333-277040 40357
2024-02-14 SC 13G/A formsc13ga.htm 0001493152-24-006624 005-88651 24637793 34 101903
2024-02-14 SC 13G/A deeptrack-imux123123a2.htm 0001172661-24-000925 005-88651 24632660 34 103323
2024-02-14 SC 13G/A IMMUNIC, INC. 0000902664-24-001577 005-88651 24632398 34 64200
2024-02-13 S-3 FORM S-3 0001193805-24-000203 333-277040 24626708 33 334988
2024-02-05 DEF 14A e619216_def14a-immunic.htm 0001193805-24-000129 001-36201 24594145 34 675368
2024-01-24 PRE 14A e619200_pre14a-immunic.htm 0001193805-24-000089 001-36201 24557403 34 654477
2024-01-19 4 xslF345X05/e619199_4-duane.xml 0001193805-24-000069 5425
2024-01-19 4 xslF345X05/e619198_4-vitt.xml 0001193805-24-000068 5532
2024-01-19 4 xslF345X05/e619197_4-muehler.xml 0001193805-24-000067 5555
2024-01-19 4 FORM 4 0001193805-24-000066 5593
2024-01-19 D xslFormDX01/primary_doc.xml 06b 0001193805-24-000065 021-502974 24545604 33 17527
2024-01-18 SC 13G SCHEDULE 13G 0000921895-24-000094 005-88651 24542064 34 287209
2024-01-18 SC 13G JHG PLC OWNS 7.4% 0001274173-24-000002 005-88651 24540757 34 13070
2024-01-16 SC 13G d10934644_13g.htm 0000919574-24-000383 005-88651 24535290 34 170762
2024-01-10 SC 13G SCHEDULE 13G 0001213900-24-002473 005-88651 24525006 34 149970
2024-01-05 8-K e619173_8k-immunic.htm 1.01,3.02,7.01,8.01,9.01 0001193805-24-000022 001-36201 24514407 34 8988302 1 1
2023-12-21 8-K e619130_8k-immunic.htm 5.02,9.01 0001193805-23-001637 001-36201 231502884 34 923245 1 1
2023-11-30 UPLOAD filename1.pdf 0000000000-23-013078 333-275717 40369
2023-11-22 S-3 e619076_s3-immunic.htm 0001193805-23-001527 333-275717 231433756 33 715024
2023-11-14 10-Q 10-Q 0001280776-23-000018 001-36201 231401578 34 5387908 1 1
2023-11-14 8-K e619056_8k-immunic.htm 2.02,8.01,9.01 0001193805-23-001486 001-36201 231401464 34 4552431 1 1
2023-10-18 8-K e619010_8k-immunic.htm 1.01,9.01 0001193805-23-001425 001-36201 231332289 34 203206 1 1
2023-10-10 8-K e618990_8k-immunic.htm 8.01,9.01 0001193805-23-001384 001-36201 231315882 34 7232457 1 1
2023-08-21 S-8 e618885_s8-immunic.htm 0001193805-23-001200 333-274099 231187259 33 362883
2023-08-03 10-Q 10-Q 0001280776-23-000013 001-36201 231137956 34 5310493 1 1
2023-08-03 8-K e618816_8k-immunic.htm 2.02,8.01,9.01 0001193805-23-001054 001-36201 231137946 34 3855534 1 1
2023-06-30 8-K e618747_8k-immunic.htm 5.07 0001193805-23-000931 001-36201 231059616 34 199826 1 1
2023-06-29 4 xslF345X04/e618746_4-howson.xml 0001193805-23-000923 5181
2023-06-29 4 xslF345X04/e618745_4-phillips.xml 0001193805-23-000921 5327
2023-06-29 4 xslF345X04/e618744_4-rudick.xml 0001193805-23-000919 5313
2023-06-29 4 xslF345X04/e618743_4-jorg.xml 0001193805-23-000917 5304
2023-06-29 4 xslF345X04/e618742_4-toernsen.xml 0001193805-23-000915 5352
2023-05-16 4 FORM 4 0001193805-23-000735 4831
2023-05-11 8-K e618615_8k-immunic.htm 2.02,8.01,9.01 0001193805-23-000700 001-36201 23909076 34 3879463 1 1
2023-05-11 10-Q 10-Q 0001280776-23-000010 001-36201 23908722 34 5518103 1 1
2023-05-04 8-K e618584_8k-immunic.htm 8.01,9.01 0001193805-23-000659 001-36201 23886327 34 12186243 1 1
2023-05-01 DEF 14A e618561_def14a-immunic.htm 0001193805-23-000637 001-36201 23874753 34 755918
2023-04-27 4 xslF345X04/e618551_4-rudick.xml 0001193805-23-000613 5315
2023-04-27 3 xslF345X02/e618550_3-rudick.xml 0001193805-23-000612 2957
2023-04-27 8-K FORM 8-K 5.02,9.01 0001193805-23-000611 001-36201 23851744 34 224660 1 1
2023-04-05 8-K FORM 8-K 8.01,9.01 0001193805-23-000500 001-36201 23801119 34 6379433 1 1
2023-03-13 8-K FORM 8-K 7.01 0001193805-23-000309 001-36201 23725823 34 196648 1 1
2023-02-24 SC 13D/A SC 13D/A 0001193125-23-047459 005-88651 23662310 34 52124
2023-02-23 10-K 10-K 0001280776-23-000004 001-36201 23655865 34 7906650 1 1
2023-02-23 8-K e618296_8k-immunic.htm 2.02,8.01,9.01 0001193805-23-000241 001-36201 23655846 34 2813406 1 1
2023-02-14 SC 13G/A formsc13ga.htm 0001493152-23-004853 005-88651 23628836 34 103299
2023-02-14 SC 13G/A IMMUNIC, INC. 0000902664-23-001718 005-88651 23623845 34 62107
2023-02-14 SC 13G/A deeptrack-imux123122a1.htm 0001172661-23-000832 005-88651 23622931 34 103536
2023-02-13 SC 13D/A SC 13D/A 0001193125-23-035951 005-88651 23619211 34 173517
2023-02-09 8-K e618255_8k-immunic.htm 8.01,9.01 0001193805-23-000100 001-36201 23601050 34 14071519 1 1
2023-01-20 8-K FORM 8-K 5.02,9.01 0001193805-23-000064 001-36201 23538771 34 268958 1 1
2023-01-06 4 xslF345X03/e618185_4-muehler.xml 0001193805-23-000023 5441
2023-01-06 4 xslF345X03/e618184_4-duane.xml 0001193805-23-000022 5311
2023-01-06 4 xslF345X03/e618183_4-whaley.xml 0001193805-23-000021 5459
2023-01-06 4 xslF345X03/e618182_4-vitt.xml 0001193805-23-000020 5415
2022-12-30 8-K e618165_8k-immunic.htm 1.01,9.01 0001193805-22-001809 001-36201 221502079 34 204875 1 1
2022-12-20 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-12-20 17:00:00 9999999995-22-003591 333-268737 221476423 33 1806
2022-12-20 424B3 e618140_424b3-immunic.htm 0001193805-22-001753 333-268737 221475601 33 211372
2022-12-16 CORRESP filename1.htm 0001193805-22-001740 5204
2022-12-15 UPLOAD filename1.pdf 0000000000-22-013534 40247
2022-12-15 4 xslF345X03/e618126_4-jorg.xml 0001193805-22-001729 7021
2022-12-09 S-3 e618097_s3-immunic.htm 0001193805-22-001680 333-268737 221455338 33 304102
2022-11-28 SC 13G SC 13G 0001193125-22-293133 005-88651 221422639 34 47846
2022-11-25 4 xslF345X03/e618059_4-jorg.xml 0001193805-22-001609 4488
2022-11-25 SC 13G SC 13G 0001193125-22-292371 005-88651 221417999 34 49105
2022-11-25 SC 13G SC 13G 0001193125-22-292368 005-88651 221417994 34 48275
2022-11-23 4 xslF345X03/e618054_4-vitt.xml 0001193805-22-001602 4972
2022-11-17 8-K e618035_8k-immunic.htm 8.01,9.01 0001193805-22-001568 001-36201 221396780 34 7665174 1 1
2022-11-08 4 xslF345X03/e618003_4-whaley.xml 0001193805-22-001497 4781
2022-11-03 10-Q 10-Q 0001280776-22-000021 001-36201 221356784 34 7725033 1 1
2022-11-03 8-K e617987_8k-immunic.htm 2.02,8.01,9.01 0001193805-22-001472 001-36201 221356060 34 3784973 1 1
2022-10-24 SC 13G SCHEDULE 13G 0000899140-22-000756 005-88651 221326369 34 59202
2022-10-21 SC 13G formsc13g.htm 0001493152-22-029364 005-88651 221324384 34 104576
2022-10-20 8-K e621964_8k-immunic.htm 8.01,9.01 0001193805-22-001439 001-36201 221321492 34 221201 1 1
2022-10-20 SC 13G deeptrack-imux101022.htm 0001172661-22-002221 005-88651 221321255 34 103501
2022-10-18 D xslFormDX01/primary_doc.xml 06b 0001193805-22-001424 021-462122 221316075 33 16364
2022-10-11 8-K e621975_8k-immunic.htm 1.01,3.02,7.01,9.01 0001193805-22-001344 001-36201 221302452 34 681304 1 1
2022-09-20 8-K e621930_8k-immunic.htm 8.01,9.01 0001193805-22-001285 001-36201 221252099 34 10982808 1 1
2022-08-04 8-K/A e621858_8ka-immunic.htm 8.01,9.01 0001193805-22-001143 001-36201 221136495 34 4942067 1 1
2022-08-04 10-Q 10-Q 0001280776-22-000017 001-36201 221134581 34 7084947 1 1
2022-08-04 8-K e621857_8k-immunic.htm 2.02,8.01,9.01 0001193805-22-001141 001-36201 221134531 34 5051935 1 1
2022-07-11 4 xslF345X03/e621829_4-toernsen.xml 0001193805-22-001090 5433
2022-07-11 3 xslF345X02/e621828_3-toernsen.xml 0001193805-22-001089 2997
2022-07-08 8-K e621820_8k-immunic.htm 5.02,9.01 0001193805-22-001069 001-36201 221072441 34 224636 1 1
2022-06-21 8-K e621762_8k-immunic.htm 5.07 0001193805-22-000976 001-36201 221026193 34 196752 1 1
2022-06-17 4 xslF345X03/e621761_4-duane.xml 0001193805-22-000974 5435
2022-06-17 4 xslF345X03/e621760_4-muehler.xml 0001193805-22-000973 5439
2022-06-17 4 xslF345X03/e621759_4-phillips.xml 0001193805-22-000972 5295
2022-06-17 4 xslF345X03/e621758_4-ossipow.xml 0001193805-22-000971 5249
2022-06-17 4 xslF345X03/e621757_4-jorg.xml 0001193805-22-000970 5272
2022-06-17 4 xslF345X03/e621756_4-whaley.xml 0001193805-22-000969 5457
2022-06-17 4 xslF345X03/e621755_4-vitt.xml 0001193805-22-000968 5407
2022-06-17 4 xslF345X03/e621754_4-howson.xml 0001193805-22-000967 5149
2022-06-17 4 xslF345X03/e621753_4-vdb.xml 0001193805-22-000966 5287
2022-06-06 4 xslF345X03/e621729_4-vitt.xml 0001193805-22-000919 4970
2022-06-06 4 xslF345X03/e621728_4-whaley.xml 0001193805-22-000918 4546
2022-06-02 8-K e621719_8k-immunic.htm 8.01,9.01 0001193805-22-000895 001-36201 22989240 34 6813737 1 1
2022-05-16 4 xslF345X03/e621657_4-muehler.xml 0001193805-22-000800 4835
2022-05-13 4 xslF345X03/e621653_4-whaley.xml 0001193805-22-000788 4544
2022-05-13 4 xslF345X03/e621652_4-duane.xml 0001193805-22-000787 6315
2022-05-10 8-K e621630_8k-immunic.htm 2.02,7.01,9.01 0001193805-22-000756 001-36201 22907259 34 13253366 1 1
2022-05-10 10-Q 10-Q 0001280776-22-000012 001-36201 22907258 34 5352657 1 1
2022-05-02 8-K e621604_8k-immunic.htm 1.01,9.01 0001193805-22-000711 001-36201 22879488 34 565230 1 1
2022-05-02 424B5 e621601_424b5-immunic.htm 0001193805-22-000710 333-250083 22879471 33 367414
2022-04-27 DEF 14A e621586_def14a-immunic.htm 0001193805-22-000690 001-36201 22856405 34 358418
2022-04-21 8-K e621584_8k-immunic.htm 7.01 0001193805-22-000679 001-36201 22841455 34 198736 1 1
2022-03-16 8-K e621458_8k-immunic.htm 1.01,5.02,9.01 0001193805-22-000504 001-36201 22743253 34 207875 1 1
2022-03-15 SC 13D/A SC 13D/A 0001193125-22-075598 005-88651 22739658 34 177225
2022-03-11 4 xslF345X03/e621442_4-duane.xml 0001193805-22-000473 5309
2022-03-11 4 xslF345X03/e621441_4-whaley.xml 0001193805-22-000472 5445
2022-02-24 10-K 10-K 0001280776-22-000006 001-36201 22666488 34 7507090 1 1
2022-02-24 8-K e621383_8k-immunic.htm 2.02,8.01,9.01 0001193805-22-000385 001-36201 22666422 34 6895775 1 1
2022-02-18 8-K e621370_8k-immunic.htm 8.01,9.01 0001193805-22-000365 001-36201 22650809 34 237021 1 1
2022-02-14 SC 13G IMMUNIC, INC. 0000902664-22-001585 005-88651 22625448 34 69244
2022-02-09 SC 13G/A filing.txt 0000315066-22-001009 005-88651 22604307 34 8447
2022-01-10 8-K e621200_8k-immunic.htm 5.02,8.01,9.01 0001193805-22-000023 001-36201 22519749 34 12134794 1 1
2022-01-06 4 xslF345X03/e621197_4-vitt.xml 0001193805-22-000018 5416
2022-01-06 4 xslF345X03/e621196_4-muehler.xml 0001193805-22-000017 5442
2022-01-06 4 xslF345X03/e621195_4-whaley.xml 0001193805-22-000016 5445
2022-01-03 5 xslF345X03/e621189_5-duane.xml 0001193805-22-000002 4773
2021-12-14 8-K e621156_8k-immunic.htm 8.01,9.01 0001193805-21-001749 001-36201 211489742 34 19302066 1 1
2021-11-04 8-K e621058_8k-immunic.htm 2.02,8.01,9.01 0001193805-21-001531 001-36201 211379810 34 2808064 1 1
2021-11-04 10-Q 10-Q 0001280776-21-000023 001-36201 211377903 34 5431636 1 1
2021-10-15 8-K e621010_8k-immunic.htm 5.02,9.01 0001193805-21-001455 001-36201 211326113 34 336428 1 1
2021-08-11 4 xslF345X03/e620867_4-whaley.xml 0001193805-21-001163 5093
2021-08-11 4 xslF345X03/e620866_4-vitt.xml 0001193805-21-001161 4969
2021-08-11 4 xslF345X03/e620865_4-duane.xml 0001193805-21-001159 4524
2021-08-06 8-K e620849_8k-immunic.htm 2.02,9.01 0001193805-21-001127 001-36201 211153088 34 299784 1 1
2021-08-06 10-Q 10-Q 0001280776-21-000018 001-36201 211150902 34 5401249 1 1
2021-07-28 S-8 e620824_s8-immunic.htm 0001193805-21-001075 333-258235 211123399 33 180957
2021-07-19 8-K e620806_8k-immunic.htm 1.01,9.01 0001193805-21-001043 001-36201 211098067 34 586603 1 1
2021-07-16 424B5 e620800_424b5-immunic.htm 0001193805-21-001031 333-250083 211094400 33 585352
2021-07-14 424B5 e620798_424b5-immunic.htm 0001193805-21-001028 333-250083 211090923 33 446046
2021-07-12 8-K e620790_8k-immunic.htm 8.01,9.01 0001193805-21-001011 001-36201 211085561 34 9658401 1 1
2021-07-12 8-K e620789_8k-immunic.htm 8.01,9.01 0001193805-21-001008 001-36201 211084234 34 238330 1 1
2021-07-01 8-K e620764_8k-immunic.htm 8.01,9.01 0001193805-21-000957 001-36201 211066024 34 7053586 1 1
2021-06-14 4 xslF345X03/e620712_4-duane.xml 0001193805-21-000874 5253
2021-06-14 4 xslF345X03/e620713_4-ossipow.xml 0001193805-21-000868 5193
2021-06-14 4 xslF345X03/e620711_4-howson.xml 0001193805-21-000867 5093
2021-06-14 4 xslF345X03/e620710_4-phillips.xml 0001193805-21-000866 5239
2021-06-14 4 xslF345X03/e620709_4-jorg.xml 0001193805-21-000865 5216
2021-06-14 4 xslF345X03/e620708_4-vdb.xml 0001193805-21-000864 5231
2021-06-14 8-K e620704_8k-immunic.htm 5.02,5.07,8.01,9.01 0001193805-21-000860 001-36201 211014780 34 18661255 1 1
2021-05-12 4 xslF345X03/e620591_4-duane.xml 0001193805-21-000654 4467
2021-05-06 8-K e620558_8k-immunic.htm 2.02,9.01 0001193805-21-000608 001-36201 21895904 34 280121 1 1
2021-05-06 10-Q 10-Q 0001280776-21-000013 001-36201 21895892 34 4768689 1 1
2021-05-05 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-05-05 09:00:00 9999999995-21-001804 333-255303 21895506 33 1748
2021-05-03 CORRESP filename1.htm 0001193805-21-000592 5326
2021-04-27 DEF 14A e620513_def14a-immunic.htm 0001193805-21-000540 001-36201 21855886 34 553509
2021-04-22 UPLOAD filename1.pdf 0000000000-21-005015 40206
2021-04-19 8-K e620493_8k-immunic.htm 1.01,5.02,9.01 0001193805-21-000513 001-36201 21835373 34 206375 1 1
2021-04-19 4 xslF345X03/e620490_4-duane.xml 0001193805-21-000512 5262
2021-04-16 S-3 e620479_s3-immunic.htm 0001193805-21-000505 333-255303 21831894 33 202197
2021-03-31 8-K e620436_8k-immunic.htm 1.01,3.02,9.01 0001193805-21-000441 001-36201 21793653 34 272179 1 1
2021-03-15 4 xslF345X03/e620386_4-muehler.xml 0001193805-21-000368 5320
2021-03-15 3 xslF345X02/e620385_3-muehler.xml 0001193805-21-000367 9802
2021-03-03 4 xslF345X03/e620352_4-whaley.xml 0001193805-21-000324 4476
2021-03-02 4 xslF345X03/e620344_4-whaley.xml 0001193805-21-000309 5388
2021-03-02 4 xslF345X03/e620343_4-groppel.xml 0001193805-21-000308 5377
2021-03-02 4 xslF345X03/e620342_4-vitt.xml 0001193805-21-000307 5359
2021-02-26 10-K 10-K 0001280776-21-000009 001-36201 21683765 34 9818417 1 1
2021-02-26 8-K e620322_8k-immunic.htm 2.02,8.01,9.01 0001193805-21-000273 001-36201 21683722 34 21572450 1 1
2021-02-19 SC 13G SC 13G 0001193125-21-048288 005-88651 21651993 34 42946
2021-02-18 8-K e620306_8k-immunic.htm 8.01,9.01 0001193805-21-000241 001-36201 21647688 34 17133334 1 1
2021-02-16 SC 13G/A SC 13G/A 0001193125-21-042148 005-88651 21631486 34 173678
2021-02-12 SC 13G/A AMENDMENT TO FORM SC 13G 0001387131-21-002203 005-88651 21624911 34 98307
2021-02-08 SC 13G filing.txt 0000315066-21-001064 005-88651 21599623 34 8271
2021-01-04 8-K e620187_8k-immunic.htm 1.01,9.01 0001193805-21-000002 001-36201 21500029 34 557487 1 1
2020-12-29 424B5 e620183_424b5-immunic.htm 0001193805-20-001635 333-250083 201422814 33 373418
2020-11-24 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-11-24 16:00:00 9999999995-20-003304 333-250083 201346739 33 1749
2020-11-20 CORRESP filename1.htm 0001193805-20-001458 5140
2020-11-20 UPLOAD filename1.pdf 0000000000-20-011118 40230
2020-11-13 S-3 e620079_s3-immunic.htm 0001193805-20-001429 333-250083 201312285 33 693104
2020-11-13 8-K/A e620080_8ka-immunic.htm 1.01,9.01 0001193805-20-001425 001-36201 201311589 34 216028 1 1
2020-11-12 424B5 e620073_424b5-immunic.htm 0001193805-20-001410 333-225230 201302866 33 22873
2020-11-06 10-Q 10-Q 0001280776-20-000035 001-36201 201292389 34 9516543 1 1
2020-11-05 8-K e620063_8k-immunic.htm 2.02,7.01,9.01 0001193805-20-001389 001-36201 201290505 34 3212679 1 1
2020-10-22 4 xslF345X03/e620014_4-duane.xml 0001193805-20-001306 5268
2020-10-20 8-K e620006_8k-immunic.htm 1.01,2.03,7.01,9.01 0001193805-20-001296 001-36201 201247332 34 1273324 1 1
2020-09-21 SC 13D/A e619936_sc13da-immunic.htm 0001193805-20-001154 005-88651 201186400 34 28376
2020-09-11 8-K e619924_8k-immunic.htm 7.01,9.01 0001193805-20-001136 001-36201 201169974 34 15134390 1 1
2020-09-04 SC 13D/A SC 13D/A 0001193125-20-240090 005-88651 201162031 34 57241
2020-08-10 4 xslF345X03/e619850_4-whaley.xml 0001193805-20-000993 4477
2020-08-10 SC 13G/A AMENDMENT TO FORM SC 13G 0001387131-20-007254 005-88651 201088580 34 93667
2020-08-07 8-K e619841_8k-immunic.htm 1.01,8.01,9.01 0001193805-20-000975 001-36201 201086594 34 554498 1 1
2020-08-05 424B5 e619835_424b5-immunic.htm 0001193805-20-000959 333-225230 201078589 33 488545
2020-08-04 424B5 e619827_424b5-immunic.htm 0001193805-20-000924 333-225230 201071678 33 484348

Latest XBRL company facts

One latest value per concept from companyfacts (314 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 15.88M 2026-11-06 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
dei EntityNumberOfEmployees Entity Number of Employees employee 85 2024-08-01 2024 Q3 10-Q 2024-11-07 0001280776-24-000018
dei EntityPublicFloat Entity Public Float USD 83.10M 2025-06-30 2025 FY 10-K/A 2026-04-22 0001193805-26-000493
ffd NetFeeAmt NetFeeAmt USD 1,028.08 2026-10-01 S-8 2026-10-01 0001193805-26-001316
ffd TtlFeeAmt TtlFeeAmt USD 1,028.08 2026-10-01 S-8 2026-10-01 0001193805-26-001316
ffd TtlOfferingAmt TtlOfferingAmt USD 11.82M 2026-10-01 S-8 2026-10-01 0001193805-26-001316
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-10-01 S-8 2026-10-01 0001193805-26-001316
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 10.12M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AccountsPayableOtherCurrent Accounts Payable, Other, Current USD 638,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 20.06M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 9.80M 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD 2.75M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 819.29M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD 28.40M 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-08 0001280776-24-000009
us-gaap AdjustmentsToAdditionalPaidInCapitalOther Adjustments to Additional Paid in Capital, Other USD 0 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 13.91M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 9,000 2023-07-01 2023-09-30 2023 Q3 10-Q 2023-11-14 0001280776-23-000018
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 25.16B 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 32.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-03 0001280776-22-000021
us-gaap Assets Assets USD 136.42M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AssetsCurrent Assets, Current USD 135.09M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 93.74M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap BusinessAcquisitionsProFormaNetIncomeLoss Business Acquisition, Pro Forma Net Income (Loss) USD -19.30M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001280776-20-000009
us-gaap BusinessAcquisitionsProFormaRevenue Business Acquisition, Pro Forma Revenue USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001280776-20-000009
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 131.96M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -3.73M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 131.96M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 116.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights Class of Warrant or Right, Exercise Price of Warrants or Rights (Deprecated 2014-01-31) USD/Warrant 95.21 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 3,719.6 2019-09-25 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 240,620 2017-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap CommitmentsAndContingencies Commitments and Contingencies USD 6.80M 2020-03-31 2020 Q1 10-Q 2020-05-08 0001280776-20-000015
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 64.96M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap CommonStockDividendsPerShareCashPaid Common Stock, Dividends, Per Share, Cash Paid USD/shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap CommonStockDividendsPerShareDeclared Common Stock, Dividends, Per Share, Declared USD/shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 500.00M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 12.04M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 12.04M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap CommonStockValue Common Stock, Value, Issued USD 1,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -108.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ContractualObligation Contractual Obligation USD 1.20M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap ConversionOfStockSharesIssued1 Conversion of Stock, Shares Issued shares 3.27M 2003-05-23 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 1 2014-04-30 2015 Q3 10-Q 2015-11-05 0001628280-15-008337
us-gaap ConvertiblePreferredStockSharesReservedForFutureIssuance Convertible Preferred Stock, Shares Reserved for Future Issuance shares 16.01M 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap CostOfGoodsAndServicesSold Cost of Goods and Services Sold USD 13,000 2003-05-23 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption Cumulative Effect of New Accounting Principle in Period of Adoption (Deprecated 2020-01-31) USD 12,000 2019-01-01 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001280776-20-000009
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 7.30M 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price USD/shares 1 2026-04-01 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap DeferredCompensationArrangementWithIndividualCompensationExpense Deferred Compensation Arrangement with Individual, Compensation Expense USD 27,000 2012-02-01 2012-02-29 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap DeferredCompensationShareBasedArrangementsLiabilityCurrent Deferred Compensation Share-based Arrangements, Liability, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap DeferredCreditsAndOtherLiabilitiesCurrent Deferred Credits and Other Liabilities, Current USD 0 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap DeferredFinanceCostsCurrentNet Debt Issuance Costs, Current, Net USD 3.51M 2013-12-31 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap DeferredIncomeCurrent Deferred Income, Current USD 0 2020-09-30 2020 Q3 10-Q 2020-11-06 0001280776-20-000035
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0001280776-25-000005
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap DeferredRentCreditCurrent Deferred Rent Credit, Current USD 22,000 2018-12-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 41,000 2018-12-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 2.09M 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 119.87M 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2019-12-31 2019 FY 10-K 2020-03-16 0001280776-20-000009
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsForeign Deferred Tax Assets, Operating Loss Carryforwards, Foreign USD 90.64M 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 24.48M 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 207,000 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 0 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 6.06M 2016-12-31 2016 FY 10-K 2017-03-07 0001280776-17-000010
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 2.45M 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap DeferredTaxAssetsUnrealizedCurrencyLosses Deferred Tax Assets, Unrealized Currency Losses USD 0 2024-12-31 2024 FY 10-K 2025-03-31 0001280776-25-000005
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 119.87M 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 0 2022-12-31 2022 FY 10-K 2023-02-23 0001280776-23-000004
us-gaap Depreciation Depreciation USD 99,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0001280776-24-000018
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 105,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 105,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) USD 113.91M 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap DirectCostsOfLeasedAndRentedPropertyOrEquipment Direct Costs of Leased and Rented Property or Equipment USD 999,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -2.83 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -3.33 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-04 0001280776-21-000023
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -2.83 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.176 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-22 0001280776-24-000004
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure 0.028 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent pure 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-22 0001280776-24-000004
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent pure 0.038 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.014 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001280776-17-000010
us-gaap EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent pure -0.009 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent pure -0.004 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.002 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent pure 0 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-08 0001628280-16-012388
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.029 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001280776-17-000010
us-gaap EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations USD -1,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD -553,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 335,000 2019-09-30 2019 Q3 10-Q 2019-11-07 0001280776-19-000056
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 11.00M 2023-12-31 2023 FY 10-K 2024-02-22 0001280776-24-000004
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 900,000 2024-03-31 2024 Q1 10-Q 2024-05-08 0001280776-24-000009
us-gaap FairValueAssumptionsExercisePrice Fair Value Assumptions, Exercise Price (Deprecated 2018-01-31) USD 8 2013-12-01 2015 FY 10-K 2016-03-08 0001628280-16-012388
us-gaap FairValueAssumptionsExpectedDividendRate Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) pure 0 2018-01-01 2018-06-30 2018 Q2 10-Q 2018-08-07 0001280776-18-000079
us-gaap FairValueAssumptionsExpectedVolatilityRate Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) pure 0.85 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-08 0001628280-16-012388
us-gaap FairValueAssumptionsRiskFreeInterestRate Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) pure 0.004 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-08 0001628280-16-012388
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings USD 23.60M 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) USD 4.80M 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value USD 0 2024-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap ForeignCurrencyTransactionGainLossUnrealized Foreign Currency Transaction Gain (Loss), Unrealized USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-13 0001280776-25-000017
us-gaap GainLossOnSaleOfEquityInvestments Gain (Loss) on Sale of Equity Investments USD 0 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-06 0001280776-20-000035
us-gaap GainLossOnSaleOfInvestments Gain (Loss) on Sale of Investments USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 36.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap Goodwill Goodwill USD 0 2022-12-31 2022 FY 10-K 2023-02-23 0001280776-23-000004
us-gaap GoodwillImpairmentLoss Goodwill, Impairment Loss USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-22 0001280776-24-000004
us-gaap GovernmentAssistanceAmount GovernmentAssistanceAmount USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap GovernmentAssistanceExpense GovernmentAssistanceExpense USD 7,000 2025-04-01 2025-06-30 2025 Q2 10-Q 2025-08-07 0001280776-25-000012
us-gaap GrossProfit Gross Profit USD 9,000 2003-05-23 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 1.22M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap IncomeLossAttributableToParent Income (Loss) Attributable to Parent, before Tax USD -97.17M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple Income (Loss) from Operations before Extraordinary Items (Deprecated 2019-01-31) USD -113.92M 2003-05-23 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -41.47M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -41.48M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD -8,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -20.41M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 196,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 315,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 1.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap IncreaseDecreaseInDerivativeLiabilities Increase (Decrease) in Derivative Liabilities USD 4,796 2024-01-01 2024-03-31 2024 Q3 10-Q 2024-11-07 0001280776-24-000018
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -419,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap IncreaseDecreaseInOtherCurrentLiabilities Increase (Decrease) in Other Current Liabilities USD 5.96M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-14 0001280776-23-000018
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD 745,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -4.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap IncreaseDecreaseInRestrictedCash Increase (Decrease) in Restricted Cash USD 75,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-16 0001280776-20-000009
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 1.34M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap InterestExpense Interest Expense USD 413,000 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 32,000 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-06 0001280776-20-000035
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 3.14M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap InvestmentIncomeInvestmentExpense Investment Income, Investment Expense USD 1,000 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-16 0001280776-20-000009
us-gaap IssuanceOfStockAndWarrantsForServicesOrClaims Issuance of Stock and Warrants for Services or Claims USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-23 0001280776-23-000004
us-gaap LeaseholdImprovementsGross Leasehold Improvements, Gross USD 478,000 2013-12-31 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 544,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 279,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 197,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 68,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 41,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap Liabilities Liabilities USD 31.95M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 136.42M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LiabilitiesCurrent Liabilities, Current USD 31.55M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LiabilitiesFairValueDisclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure USD 809,000 2025-12-31 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap LiabilitiesFairValueDisclosureRecurring Liabilities, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) USD 0 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap LiabilitiesNoncurrent Liabilities, Noncurrent USD 400,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ManagementFeeExpense Management Fee Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 194.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 29.96M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-08 0001280776-19-000051
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -355,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD 9.32M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-08 0001280776-19-000051
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -76.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -16.30M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-08 0001280776-19-000051
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -109.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -52.08M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income (Deprecated 2020-01-31) USD 5,000 2003-05-23 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1 Noncash or Part Noncash Acquisition, Value of Assets Acquired USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 2.94M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap NotesAndLoansReceivableNetCurrent Financing Receivable, after Allowance for Credit Loss, Current USD 920,000 2019-06-30 2019 Q2 10-Q 2019-08-08 0001280776-19-000051
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OperatingExpenses Operating Expenses USD 111.93M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -111.93M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 1.12M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 503,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 246,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 328,000 2026-06-30 2026 Q2 10-Q 2026-08-11 0001280776-26-000018
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 504,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 2.58M 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 1.07M 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 221,000 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 434,000 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 387,000 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 469,000 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 0 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 223,000 2017-09-30 2017 Q3 10-Q 2017-10-25 0001280776-17-000098
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 149,000 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.53M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OtherAssetsCurrent Other Assets, Current USD 842,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-02-22 0001280776-24-000004
us-gaap OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent USD 0 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent USD 101,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD 776,000 2023-01-01 2023-03-31 2024 Q1 10-Q 2024-05-08 0001280776-24-000009
us-gaap OtherDeferredCreditsCurrent Other Deferred Credits, Current USD 663,000 2020-03-31 2020 Q1 10-Q 2020-05-08 0001280776-20-000015
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 1.37M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 400,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -119,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -204,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap OtherOperatingActivitiesCashFlowStatement Other Operating Activities, Cash Flow Statement USD 0 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap OtherShortTermInvestments Other Short-term Investments USD 0 2023-12-31 2023 FY 10-K 2024-02-22 0001280776-24-000004
us-gaap OtherSundryLiabilitiesCurrent Other Sundry Liabilities, Current USD 1.13M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap PaidInKindInterest Paid-in-Kind Interest USD 382,000 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap PaymentsForCommissions Payments for Commissions USD 0 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap PaymentsForProceedsFromInvestments Payments for (Proceeds from) Investments USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0001280776-25-000005
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 0 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 9,000 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-14 0001280776-23-000018
us-gaap PaymentsToAcquireIntangibleAssets Payments to Acquire Intangible Assets USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap PaymentsToAcquireOtherInvestments Payments to Acquire Other Investments USD 9.63M 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-23 0001280776-23-000004
us-gaap PaymentsToAcquireProductiveAssets Payments to Acquire Productive Assets USD 75,000 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-07 0001280776-19-000056
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 355,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap PaymentsToAcquireShortTermInvestments Payments to Acquire Short-term Investments USD 0 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-08 0001628280-16-012388
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 20.00M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 3.12M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap PrepaidInsurance Prepaid Insurance USD 671,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs USD 0 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-15 0001280776-25-000008
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-06 0001280776-21-000013
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 0 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-08 0001280776-20-000015
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 690.00M 2019-04-15 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised USD 86,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ProceedsFromSaleOfMachineryAndEquipment Proceeds from Sale of Machinery and Equipment USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap ProceedsFromSaleOfOtherInvestments Proceeds from Sale of Other Investments USD 9.80M 2023-01-01 2023-06-30 2023 Q2 10-Q 2023-08-03 0001280776-23-000013
us-gaap ProceedsFromSaleOfOtherPropertyPlantAndEquipment Proceeds from Sale of Other Property, Plant, and Equipment USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap ProceedsFromSaleOfProductiveAssets Proceeds from Sale of Productive Assets USD 9.80M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-14 0001280776-23-000018
us-gaap ProceedsFromSaleOfShortTermInvestments Proceeds from Sale of Short-term Investments USD 0 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-08 0001628280-16-012388
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 321,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0001280776-25-000005
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -52.08M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 10.28M 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 832,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ProvisionForLoanLeaseAndOtherLosses Provision for Loan, Lease, and Other Losses USD 416,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap PurchaseObligation Purchase Obligation USD 431,000 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap PurchaseObligationDueAfterFifthYear Purchase Obligation, to be Paid, after Year Five USD 0 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap PurchaseObligationDueInFourthAndFifthYear Purchase Obligation, to be Paid, Year Four and Five USD 0 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap PurchaseObligationDueInNextTwelveMonths Purchase Obligation, to be Paid, Year One USD 431,000 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap PurchaseObligationDueInSecondAndThirdYear Purchase Obligation, to be Paid, Year Two and Three USD 0 2017-12-31 2017 FY 10-K 2018-03-13 0001280776-18-000013
us-gaap RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction USD 72,000 2019-05-01 2019-05-31 2019 Q2 10-Q 2019-08-08 0001280776-19-000051
us-gaap RepaymentsOfLongTermDebt Repayments of Long-term Debt USD 533,000 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 75.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap RestrictedCash Restricted Cash EUR 18.20M 2019-03-31 2020 Q1 10-Q 2020-05-08 0001280776-20-000015
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 0 2020-03-31 2020 Q1 10-Q 2020-05-08 0001280776-20-000015
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 0 2016-12-31 2016 FY 10-K 2017-03-07 0001280776-17-000010
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -717.57M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 345,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap SalesRevenueNet Revenue, Net (Deprecated 2018-01-31) USD 22,000 2003-05-23 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap SeveranceCosts1 Severance Costs USD 6.37M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 25.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost Share-based Payment Arrangement, Accelerated Cost USD 1.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date pure 0.06 2013-09-30 2015 FY 10-K 2016-03-08 0001628280-16-012388
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 0.25 2018-01-01 2018-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 1.15 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-13 0001280776-26-000010
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.8 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-13 0001280776-26-000010
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.042 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-13 0001280776-26-000010
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.038 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-13 0001280776-26-000010
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate pure 0.81 2014-01-01 2014-03-31 2014 Q1 10-Q 2014-05-28 0001193125-14-215136
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant shares 163,627 2016-09-30 2016 Q3 10-Q 2016-11-03 0001280776-16-000026
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 0 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 500,000 2025-07-07 2026 Q1 10-Q 2026-05-13 0001280776-26-000010
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 7.17 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 2,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 4.69M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 6.33 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 27,230 2012-02-01 2012-02-29 2014 FY 10-K 2015-03-20 0001193125-15-098980
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 35,408 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-09 0001280776-17-000029
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 0 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 4.4 2018-01-01 2018-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 0 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 1.49M 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 7.08 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 0 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 1.48M 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 7.09 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Payment Arrangement, Plan Modification, Incremental Cost USD 1.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 5.35 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 6.05 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap SharePrice Share Price USD/shares 12.87 2019-06-30 2019 Q2 10-Q 2019-08-08 0001280776-19-000051
us-gaap SharesIssuedPricePerShare Shares Issued, Price Per Share USD/shares 5.5 2015-10-31 2016 FY 10-K 2017-03-07 0001280776-17-000010
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 104.47M 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.025 2019-04-12 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap StockIssued1 Stock Issued USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-23 0001280776-23-000004
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 460,336 2018-12-01 2018-12-31 2019 Q2 10-Q 2019-08-08 0001280776-19-000051
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 0 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap StockIssuedDuringPeriodValueAcquisitions Stock Issued During Period, Value, Acquisitions USD 39.40M 2019-01-01 2019-12-31 2020 FY 10-K 2021-02-26 0001280776-21-000009
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 0 2025-04-01 2025-06-30 2025 Q3 10-Q 2025-11-13 0001280776-25-000017
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 86,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 89,000 2018-01-01 2018-03-31 2019 Q1 10-Q 2019-04-10 0001280776-19-000032
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 5,000 2022-01-01 2022-03-31 2023 Q3 10-Q 2023-11-14 0001280776-23-000018
us-gaap StockIssuedDuringPeriodValueOther Stock Issued During Period, Value, Other USD 0 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-07 0001280776-17-000010
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 289,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap TangibleAssetImpairmentCharges Tangible Asset Impairment Charges USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap TemporaryEquityAccretionToRedemptionValueAdjustment Temporary Equity, Accretion to Redemption Value, Adjustment USD 0 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001280776-17-000010
us-gaap TemporaryEquityDividendsAdjustment Temporary Equity, Dividends, Adjustment USD 0 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-07 0001280776-17-000010
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 108,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-04 0001280776-19-000025
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 2.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001280776-26-000005
us-gaap ValueAddedTaxReceivableCurrent Value Added Tax Receivable, Current USD 410,000 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 38.51M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 21.56M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-04 0001280776-21-000023
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 38.51M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-13 0001280776-26-000021

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →